CAR T Cell Locomotion in Solid Tumor Microenvironment
Authors:
- Duy T. NguyenDNDuy T. Nguyen
- Elizabeth Ogando-RivasEOElizabeth Ogando-Rivas
- Ruixuan LiuRLRuixuan Liu
- Theodore WangTheodore Wang
- Jacob RubinJRJacob Rubin
- Linchun JinLJLinchun Jin
- Haipeng TaoHTHaipeng Tao
- William W. SawyerWSWilliam W. Sawyer
- Hector R. Mendez-GomezHMHector R. Mendez-Gomez
- Matthew CascioMCMatthew Cascio
- Duane A. MitchellDMDuane A. Mitchell
- Jianping HuangJHJianping Huang
Open Access
Abstract
The promising outcomes of chimeric antigen receptor (CAR) T cell therapy in hematologic malignancies potentiates its capability in the fight against many cancers. Nevertheless, this immunotherapy modality needs significant improvements for the treatment of solid tumors. Researchers have incrementally identified limitations and constantly pursued better CAR designs. However, even if CAR T cells are armed with optimal killer functions, they must overcome and survive suppressive barriers imposed by the tumor microenvironment (TME). In this review, we will discuss in detail the important role of TME in CAR T cell trafficking and how the intrinsic barriers contribute to an immunosuppressive phenotype and cancer progression. It is of critical importance that preclinical models can closely recapitulate the in vivo TME to better predict CAR T activity. Animal models have contributed immensely to our understanding of human diseases, but the intensive care for the animals and unreliable representation of human biology suggest in vivo models cannot be the sole approach to CAR T cell therapy. On the other hand, in vitro models for CAR T cytotoxic assessment offer valuable insights to mechanistic studies at the single cell level, but they often lack in vivo complexities, inter-individual heterogeneity, or physiologically relevant spatial dimension. Understanding the advantages and limitations of preclinical models and their applications would enable more reliable prediction of better clinical outcomes.Keywords
Funding Information
- National Science Foundation Graduate Research Fellowship (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- NCI (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- Rally Foundation (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- Bankhead Coley Research Grant (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- Live Like Bella Discovery grant (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- University of Florida Health Cancer Center / University of Florida and Florida State University Clinical and Translational Science Awards (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
- STOP Children’s Cancer Foundation (DGE-1842473, R37CA251978, P0216283, P0172137, 22L07, KL2TR001429, UL1TR001427, F023891)
This publication has 283 references indexed in Scilit:
- Alginate: Properties and biomedical applicationsProgress in Polymer Science, 2012
- Mechanosensing in T Lymphocyte ActivationBiophysical Journal, 2012
- Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and MetastasisCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor ProgressionCancer Cell, 2011
- Confinement-optimized three-dimensional T cell amoeboid motility is modulated via myosin IIA–regulated adhesionsNature Immunology, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and PeripheryImmunity, 2008